Minerva Neurosciences (NERV) EBITDA (2013 - 2026)

Minerva Neurosciences has reported EBITDA for 14 years, with the latest figure at -$16.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 327.16% year-over-year to -$16.7 million; the trailing twelve-month figure through Mar 2026 stood at -$27.9 million (down 46.16% YoY), and the FY2025 full-year result was -$15.1 million, up 30.87% from the prior year.
• EBITDA for Q1 2026 stood at -$16.7 million, down from -$5.0 million in the prior quarter.
• The five-year high for EBITDA was -$2.8 million in Q3 2025, with the low at -$16.7 million in Q1 2026.
• Historically, EBITDA has averaged -$6.0 million across 5 years, with a median of -$5.2 million in 2022.
• Annual changes were most pronounced in 2022 — EBITDA jumped 76.28% — and 2026, when it plunged 327.16%.
• Minerva Neurosciences' EBITDA stood at -$5.1 million in 2022, then sank by 41.47% to -$7.2 million in 2023, then soared by 36.95% to -$4.5 million in 2024, then dropped by 10.16% to -$5.0 million in 2025, then sank by 234.66% to -$16.7 million in 2026.
• The last three EBITDA figures came in at -$16.7 million (Q1 2026), -$5.0 million (Q4 2025), and -$2.8 million (Q3 2025), per Business Quant data.